stoxline Quote Chart Rank Option Currency Glossary
Nurix Therapeutics, Inc. (NRIX)
16.73  0.23 (1.39%)    06-13 16:00
Open: 16.51
High: 17.25
Volume: 1,166,786
Pre. Close: 16.5
Low: 16.31
Market Cap: 992(M)
Technical analysis
2024-06-13 4:45:12 PM
Short term     
Mid term     
Targets 6-month :  20.18 1-year :  23.57
Resists First :  17.28 Second :  20.18
Pivot price 15.85
Supports First :  14.77 Second :  13.22
MAs MA(5) :  16.07 MA(20) :  15.9
MA(100) :  13.12 MA(250) :  10.2
MACD MACD :  0.4 Signal :  0.4
%K %D K(14,3) :  71.6 D(3) :  55.6
RSI RSI(14): 59.7
52-week High :  18.12 Low :  4.21
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NRIX ] has closed below upper band by 10.5%. Bollinger Bands are 41.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.28 - 17.35 17.35 - 17.42
Low: 16.15 - 16.21 16.21 - 16.29
Close: 16.61 - 16.74 16.74 - 16.86
Company Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Headline News

Wed, 12 Jun 2024
Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells 1,900 Shares of Stock - MarketBeat

Tue, 11 Jun 2024
Nurix Therapeutics (NASDAQ:NRIX) Trading 3.5% Higher - MarketBeat

Tue, 11 Jun 2024
Financial Contrast: Nurix Therapeutics (NASDAQ:NRIX) versus HCW Biologics (NASDAQ:HCWB) - Defense World

Mon, 10 Jun 2024
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 3.9% - MarketBeat

Mon, 03 Jun 2024
Charles Schwab Investment Management Inc. Purchases 53721 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World

Mon, 03 Jun 2024
Nurix Therapeutics executive sells over $27k in company stock By -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 61 (M)
Shares Float 39 (M)
Held by Insiders 2.1 (%)
Held by Institutions 87 (%)
Shares Short 7,280 (K)
Shares Short P.Month 7,040 (K)
Stock Financials
EPS -2.67
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.43
Profit Margin -179 %
Operating Margin -272.7 %
Return on Assets (ttm) -28.8 %
Return on Equity (ttm) -65.4 %
Qtrly Rev. Growth 30.7 %
Gross Profit (p.s.) 0
Sales Per Share 1.32
EBITDA (p.s.) -2.48
Qtrly Earnings Growth 0 %
Operating Cash Flow -75 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -6.29
PEG Ratio 0
Price to Book value 4.87
Price to Sales 12.63
Price to Cash Flow -13.65
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android